A portion of EGFR-mutant NSCLC patients, treated with the third-generation of EGFR-TKIs, progresses due to the onset, as an acquired mechanism of resistance, of a tertiary EGFR-C797S mutation. Here, EGFR is linked to non-small cell lung carcinoma.